What are the recommended starting doses, titration schedule, contraindications, and monitoring parameters for nebivolol (selective β1‑adrenergic blocker) in patients with hypertension or chronic heart failure?

Nebivolol: Dosing, Titration, Contraindications, and Monitoring

Starting Dose and Titration Schedule

For heart failure with reduced ejection fraction (HFrEF), initiate nebivolol at 1.25 mg once daily and uptitrate every 1–2 weeks to a target dose of 10 mg daily. 1

• The patient must be euvolemic and clinically stable (no intravenous inotropes, no marked fluid retention) before starting nebivolol. 1
• Background ACE-inhibitor therapy should already be established unless contraindicated. 1
• The dose-escalation sequence is: 1.25 mg → 2.5 mg → 5 mg → 10 mg daily, doubling the dose every 1–2 weeks if the preceding dose was well tolerated. 1
• Most patients can be managed as outpatients during titration. 1

For hypertension, the recommended starting dose is 5 mg once daily, with or without food; if further blood pressure reduction is needed, increase at 2-week intervals up to a maximum of 40 mg daily. 2

• In patients with severe renal impairment (creatinine clearance < 30 mL/min) or moderate hepatic impairment, start at 2.5 mg once daily and titrate slowly. 2
• No dose adjustment is necessary in elderly patients or in CYP2D6 poor metabolizers. 2

Evidence Base for Heart Failure

• Nebivolol is one of only four β-blockers (along with bisoprolol, carvedilol, and metoprolol succinate) with proven mortality and morbidity benefits in heart failure; the evidence base for β-blockers in HFrEF is limited to these specific agents. 1
• In the SENIORS trial (elderly patients ≥70 years with heart failure), nebivolol reduced the composite endpoint of all-cause mortality or cardiovascular hospitalization (hazard ratio 0.86,95% CI 0.74–0.99; p=0.039). 3
• The benefit was consistent regardless of left ventricular ejection fraction (LVEF), including patients with LVEF > 35%. 3

Contraindications

Absolute contraindications to nebivolol in heart failure include asthma, severe bronchial disease, and symptomatic bradycardia or hypotension. 1

• Relative contraindications requiring specialist referral: severe heart failure (NYHA class IV), asymptomatic bradycardia, low blood pressure, intolerance to low doses, previous β-blocker discontinuation due to symptoms, or suspected severe pulmonary disease. 1

Monitoring Parameters

During β-blocker titration, monitor for heart failure symptoms, fluid retention, hypotension, and symptomatic bradycardia after each dose increase. 1

Management of Adverse Effects During Titration

• If worsening heart failure symptoms or fluid retention occur: First increase the diuretic dose or ACE-inhibitor dose; temporarily reduce nebivolol only if optimizing other medications does not resolve symptoms. 1
• If hypotension develops: First reduce the dose of vasodilators (e.g., ACE inhibitor); reduce nebivolol dose only if necessary. 1
• If symptomatic bradycardia occurs: Reduce or discontinue drugs that lower heart rate; reduce nebivolol dose if necessary, but discontinue only if clearly required. 1
• Always consider reintroduction and uptitration of nebivolol when the patient stabilizes. 1

Specific Monitoring Intervals

• Check blood pressure, renal function (creatinine), and electrolytes (potassium, sodium) at 1–2 weeks after each dose increase, then at 3 months, and subsequently every 6 months. 4
• For patients on spironolactone (often co-prescribed in advanced heart failure), measure potassium and creatinine 4–6 days after initiation and after any dose change. 4

Common Pitfalls and Caveats

• Do not start nebivolol in patients with active decompensation, marked fluid overload, or requiring intravenous inotropic support. 1
• Transient worsening of heart failure symptoms occurs in 20–30% of patients during initiation or uptitration; this is usually manageable by adjusting diuretics or ACE inhibitors rather than stopping the β-blocker. 1
• If inotropic support is needed in a patient already on nebivolol, use phosphodiesterase inhibitors (e.g., milrinone) because their hemodynamic effects are not antagonized by β-blockade. 1
• Avoid NSAIDs in patients on nebivolol and ACE inhibitors, as they worsen renal function, promote fluid retention, and blunt the therapeutic effects of both drug classes. 4
• Patients with NYHA class III–IV heart failure, unknown etiology, or relative contraindications should be referred for specialist care before initiating β-blocker therapy. 1

Tolerability Profile

• The most common adverse events in hypertension trials were headache (6–9%), dizziness (2–4%), fatigue (2–5%), and bradycardia (≤1%). 2
• Discontinuation rates due to adverse reactions were similar to placebo (2.8% vs. 2.2%). 2
• Nebivolol is generally well tolerated in patients with chronic obstructive pulmonary disease, erectile dysfunction, and does not adversely affect glucose or lipid metabolism. 5, 6, 7